Traditional AI
Most AI systems learn correlations
from historical data.
AI-powered, mechanistic digital twins •Industrial-Grade
The Decision IntelligencePlatform for Life Sciencesand Drug R&D
Simulate critical decisions before committing real-world time, capital, and patients.
Explore the Platform
- Human MechanisticDigital Twins
- Virtual PatientPopulations
- AI-PoweredDecision Making
- Regulatory-GradeEvidence
DHARMA Mechanistic Digital Twin Engine
We build AI-powered, mechanistic digital twins that model disease biology, drug mechanisms, and patient responses—turning critical decisions into testable virtual experiments.
DHARMA Approach
We model the mechanisms
that drive biological response.
- Statistical associationsMechanistic models
- Population averagesPatient-specific biology
- Black-box predictionTraceable simulation
- Single modelsIntegrated biological systems
- Retrospective analysisProspective virtual experiments
The 6-Best Framework
Differentia "6-Best": Five Critical Decisions. One Best Asset.
The Best Asset emerges when target, molecule, dosing, trial design, and segmentation are optimized together.
Best Target
Validate and prioritize targets before costly R&D
Best Molecule
Compare candidates through human mechanistic simulation
Best Dosing
Optimize exposure, efficacy and safety
Best Trial Design
Optimize endpoints, reduce 20-60% cohort size, simulate outcome before enrollment
Best Segmentation
Identify patients most likely to benefit — and why
Best Asset
Where every critical decision aligns to maximize asset value.
Higher probability of success, better clinical outcomes, and greater commercial value.
Explore the 6-Best Decisions
Pick Winners Earlier
De-risk targets, molecules and programs before major capital commitment.
Win the Market
Go to market faster with superior trial results for accelerated commercial success.
Maximize Asset Value
Generate quantitative evidence for licensing, indication expansion, and portfolio decisions.
Partners
Chosen by global industry leaders
Multiple global MNCs, biotechs, CROs and life science organizations trust Differentia to turn complex biological questions into auditable virtual experiments.
Best Target
The Challenge
No validated animal model for an inflammatory or infectious disease.
The Simulation
Simulate target efficacy, safety and combination strategies.
Eliminate Ineffective Targets Early
Best Molecule
The Challenge
Animal-to-human translation uncertainty for novel assets
The Simulation
Simulate candidate safety and efficacy in virtual patients against competitor molecule
Stop Inferior Assets Before Clinical Development
Best Dosing
The Challenge
Optimize dosing regimen
The Simulation
Simulate exposure, efficacy, toxicity and therapeutic window.
Precision-Designed Phase I-III Dosing
Best Trial Design
The Challenge
Slow enrollment
The Simulation
Simulate trial scenarios to optimize cohort size, design and outcomes.
Reduce 30%+ trial size - Preserve billions in revenue
Best Segmentation
The Challenge
Optimize Phase III to target best in class
The Simulation
Generate virtual patients from Phase I–II data; simulate subgroup efficacy, safety and outcomes
De-risked Phase III, target to be the market leader
Regulatory-grade by design
Rigorous Validation: Credible, Auditable, Regulatory-Ready
From mechanistic fidelity to clinical prediction: a 4-stage framework built for FDA MIDD alignment.
100%Explainable.
No black-box answer.
Every recommendation is connected to explicit mechanisms, evidence, assumptions, model boundaries and a traceable audit trail.
- 01Mechanistic Validity
- 02Historical Data Calibration
- 03External Validation
- 04Decision Robustness
Modelling aligned withregulatory standards &
compliance framework
- Global guidelineICH M15 aligned
- Governed records21 CFR Part 11 ready
- Regulatory pathwayFDA / EMA / CDE
One scientific foundation. Three decision domains.
R&D
Identify the best targets, molecules, dosing strategies, trials and patient populations.
Capital
Connect scientific evidence to asset prioritization, portfolio strategy, investment, licensing and M&A decisions.
Clinical
Over time, extend mechanistic digital twins toward precision medicine and individualized treatment decisions.
Start with the decision
Evaluate the decision before it becomes a real-world commitment
Whether you are evaluating a target, comparing candidates, selecting a regimen, designing a trial or defining a development population, Differentia can turn the available evidence into a controlled virtual experiment.